Arcturus slides on PhIII Covid-19 vaccine data, indicating struggle to produce follow-up shots – Endpoints News
Arcturus slides on PhIII Covid-19 vaccine data, indicating struggle to produce follow-up shots – Endpoints News

Arcturus slides on PhIII Covid-19 vaccine data, indicating struggle to produce follow-up shots – Endpoints News

Enzyvant will expand its production of regenerative medicine with a new facility in the North Carolina Research Triangle Park area.

Construction of the 25,972-square-foot plot will begin this summer and be completed around the end of 2024. It will be located in Morrisville, NC.

“I’m very pleased with the new opportunities that this new manufacturing facility will bring to Enzyvant, and I look forward to the progress we make as we look forward to realizing the effort,” said Myrtle Potter, CEO of Sumitovant, Enzyvant’s holding company. “This is a great example of three members of the Sumitomo Pharma family of companies working seamlessly together to address the most pressing issues affecting patients and families with the highest unmet medical needs.”

Leave a Reply

Your email address will not be published.